Molecular Insight Pharmaceuticals, Inc.
160 Second Street
Cambridge,
MA 02142
United States - Map
Phone: 617-492-5554
Fax: 617-492-5664
Web Site: http://www.molecularinsight.com
| Molecular Insight Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the research, development, and commercialization of molecular imaging pharmaceuticals and radiotherapeutics primarily in the areas of oncology and cardiology in the United States. Its products under development include Azedra, a clinical-stage radiotherapeutic product candidate for the treatment of metastatic neuroendocrine tumors, such as pheochromocytoma, carcinoid, and neuroblastoma; and Onalta, a clinical-stage radiotherapeutic product candidate for the radiotherapeutic treatment of metastatic carcinoid and pancreatic neuroendocrine tumors. The company also develops Zemiva, a molecular imaging pharmaceutical product for the diagnosis of cardiac ischemia or insufficient blood flow to the heart in the emergency department setting, as well as for the diagnosis of coronary disease in the non-acute setting. In addition, its products under development include Solazed, a radiotherapeutic for the treatment of malignant metastatic melanoma; Trofex, a molecular imaging pharmaceutical for detection of prostate-specific membrane antigen, an expression which would enable the detection and monitoring of prostate cancer; MIP-190 to assess the progression of heart failure through the monitoring of angiotensin converting enzyme in human hearts; and MIP-170D, a molecular imaging pharmaceutical compound to aid in the objective diagnosis of Parkinson’s disease and attention deficit hyperactivity disorder. The company was founded in 1997 as Imaging Biopharmaceuticals, Inc. and changed its name to Biostream, Inc. in 1998. Further, it changed its name to Molecular Insight Pharmaceuticals, Inc. in 2003. The company is based in Cambridge, Massachusetts. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. John W. Babich Ph.D., 50
Founder, Chairman, Interim Chief Exec. Officer, Pres and Chief Scientific Officer |
N/A
| N/A | Mr. Donald E. Wallroth , 59
Chief Financial Officer and Principal Accounting Officer |
$
175.00K | N/A | Mr. John E. McCray , 58
Chief Operating Officer |
N/A
| N/A | Mr. Norman LaFrance M.D., FACP, FACNP, 60
Chief Medical Officer and Sr. VP of Clinical Devel. |
$
294.00K | N/A | Dr. Ronald L. Van Heertum M.D,
Chief Medical Advisor and Member of Scientific Advisory Board |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-07
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
6.54% Nasdaq 
Profile
